Drugs / U-500R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02588950 | Jan 2016 → May 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U-500R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02588950 ↗ |
| Route | Subcutaneous | “Bolus of U-500R administered via single subcutaneous (SC) injection.” NCT02588950 ↗ |